Stuart L. Schreiber

About

Stuart L. Schreiber is the Morris Loeb Professor of Chemistry and Chemical Biology, Emeritus, and an Investigator at the Howard Hughes Medical Institute. His research group studies the science of therapeutics, focusing on human biology to identify validated therapeutic targets and discovering small molecules that modulate these targets to provide relief or protection from disease. His work has led to discoveries related to signaling by the phosphatase calcineurin and kinase mTOR, demonstrating that drugs can target protein kinases and phosphatases; gene regulation by chromatin-modifying histone deacetylases; small-molecule dimerizers that activate cellular processes; and small-molecule probes for challenging targets such as transcription factors, oncogenes, and protein interactions relevant to human disease. His contributions have advanced principles underlying information transfer and storage in cells, diversity-oriented synthesis, and discovery-based small-molecule screening in an open data-sharing environment. Currently, his lab investigates mechanisms of cancer resistance to therapies, exploring vulnerabilities in cell states, and studies mechanisms by which the brain maintains health, along with therapeutic agents that support brain health. His research involves discovering small-molecule binders that alter protein functions by changing their interactomes and lifetimes, utilizing modern asymmetric synthesis methods to produce candidate binders with DNA barcodes. Outside…

Research topics

• Biology
• Computational biology
• Cell biology
• Biochemistry
• Literature
• Chemistry
• Genetics

Selected publications

• Plasticity of ether lipids promotes ferroptosis susceptibility and evasion

  Nature · 2020 · 806 citations

  Senior authorCorresponding
  DOI

• Cytochrome P450 oxidoreductase contributes tophospholipid peroxidation in ferroptosis

  Nature Chemical Biology · 2020 · 695 citations

  Senior authorCorresponding
  DOI

• The Rise of Molecular Glues

  Cell · 2021 · 550 citations

  1st authorCorresponding
  DOI

• An expanded universe of cancer targets

  Cell · 2021 · 219 citations

  DOI

• Discovery of molecular glues that bind FKBP12 and structurally distinct targets using DNA-encoded libraries

  Nature Communications · 2026-04-22

  articleOpen access

  Molecular glues are small molecules that engage their target and presenter proteins cooperatively. FKBP12 molecular glues (FK506 and rapamycin) were discovered several decades ago and have been used clinically, but our understanding of the breadth of FKBP12 molecular glues and targets has yet to be fully revealed. To expand the target classes of FKBP12 molecular glues, we construct and screen a multi-million-member non-macrocyclic FKBP12-ligand DNA-encoded library using 25 structurally distinct…

  PublisherOA PDFDOI

Recent grants

• NIH Grant R01GM038627

  NIH · $11.3M · 2018

• NIH Grant U01CA176152

  NIH · $4.4M · 2018

• Studies of Materials with Physiological Properties

  NIH · $3.2M · 2018–2023

Frequent coauthors

• James E. Bradner

  Novartis (United States)

  290 shared

• Michelle Palmer

  251 shared

• Paul A. Clemons

  227 shared

• Benito Muñoz

  221 shared

• Nathan West

  207 shared

• Sivaraman Dandapani

  NKT Therapeutics (United States)

  205 shared

• Robert M. Williams

  192 shared

• Albert A. Bowers

  UNC Lineberger Comprehensive Cancer Center

  192 shared

Labs

• Schreiber GroupPI

Education

• B.A., Chemistry

  Harvard University

  1986

• Ph.D., Chemistry

  Harvard University

  1991

Awards & honors

• Novartis Faculty Scholar

Similar researchers at Harvard University

• George Whitesidesh-241
• E. J. Coreyh-150
• Daniel G. Nocerah-123